TABLE 2.

Summary of Clinical Studies with Rufinamide

STUDY TYPE	SEIZURE TYPE	DAILY DOSE	AGE (YEARS)	OUTCOME*	REFERENCE
Adjunct	Lennox–Gastaut syndrome	45 mg/kg (maximum 3,200 mg) or placebo	4 to 30	↓Drop attacks ↓Total seizures ↓Seizure severity	8
Adjunct	Partial onset	200, 400, 800, 1,600 or placebo	≥15	↓Total seizures (+) Responder rate	1
Adjunct	Partial onset	3,200 mg or placebo	≥16	↓Total seizures (+) Responder rate	1
Monotherapy	Partial onset	3,200 mg or placebo	≥12	Fewer seizures and longer time to first, second, and third seizure for rufinamide	1
Adjunct†	Primary GTC	800 mg or placebo	≥4	No difference vs. placebo	7

Abbreviations: GTC, generalized tonic–clonic.

^*All were significant (p < 0.05) except study Ref. 7.

^†The doses used did not provide patients with plasma rufinamide concentrations that are therapeutic for other seizure types, which could explain the lack of efficacy seen in this study.